Pratia LLC, part of Humaneva Group, announced in December 2025 the acquisition of a majority stake in P1 Trials, a U.S.-based early-phase-community oncology clinical research network.
“We’re excited about delivering high-quality clinical trials using our enhanced scale and wider geographical reach to benefit patients,” said Mona Alqam, MD, Country Head of the U.S. at Pratia.
P1 Trials has community-based oncology practices in Texas, Indiana and Washington state in the U.S. which provide advanced early-phase oncology studies closer to where patients receive care. The company enables community oncology practices by providing the infrastructure and support needed to conduct early-phase trials through a unified global standard.
Through this investment, Pratia and P1 are establishing one of the few global research ecosystems dedicated exclusively to early-phase oncology, connecting North America and Europe to accelerate the development of next-generation cancer treatments.
Pratia currently reaches more than 65 million patients across Europe through its integrated oncology research sites. The addition of P1’s U.S. network extends that reach and enhances both companies’ ability to deliver innovative studies in the world’s largest oncology research market.
This investment strengthens Pratia’s presence in the United States and underscores its commitment to accelerating new treatment development through closer collaboration with practicing oncologists.
“It is clear that clinical trial quality and efficacy are improved when multi-site organizations are involved,” Mona said. “Working with P1, we are looking forward to helping more patients as we advance life-saving treatments in the battle against cancer.”
According to the American Association for Cancer Research, approximately 18.6 million cancer survivors were living in the U.S. as of January 2025, while the World Health Organization estimates 3.7 million new cancer cases annually across Europe.
“The partnership with Pratia enables us to deliver a truly homogeneous research experience across continents,” said Julio Peguero, MD, President of P1 Trials. “By unifying our scientific rigor, operational standards, and patient care models, we’re building a seamless early-phase oncology network that operates with the same precision and excellence, from community practices in the U.S. to leading research centers across Europe. This alignment accelerates innovation and ensures patients everywhere gain faster access to tomorrow’s therapies.”
